| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| VRTX - Vertex Pharmaceuticals Inc | BUY | 2,154 @ USD 445.93 | USD 960,533 | The ETF bought 2154 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 445.93 compared to the previous average buy price of 421.096. This is 5.9% higher than average price of previous purchases of VRTX. |
| AMGN - Amgen Inc | BUY | 2,923 @ USD 317.38 | USD 927,702 | The ETF bought 2923 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 317.38 compared to the previous average buy price of 298.843. This is 6.2% higher than average price of previous purchases of AMGN. |
| GILD - Guild Esports Plc | BUY | 7,431 @ USD 123.21 | USD 915,574 | The ETF bought 7431 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 123.21 compared to the previous average buy price of 115.631. This is 6.6% higher than average price of previous purchases of GILD. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 1,046 @ USD 746.8 | USD 781,153 | The ETF bought 1046 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 746.8 compared to the previous average buy price of 646.492. This is 15.5% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 1,332 @ USD 412.63 | USD 549,623 | The ETF bought 1332 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 412.63 compared to the previous average buy price of 394.979. This is 4.5% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 5,263 @ USD 90.29 | USD 475,196 | The ETF bought 5263 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 90.29 compared to the previous average buy price of 78.3772. This is 15.2% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 2,152 @ USD 195.24 | USD 420,156 | The ETF bought 2152 new shares of INSM (Insmed Inc). The shares were bought for an average price of 195.24 compared to the previous average buy price of 139.701. This is 39.8% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 337 @ USD 889.49 | USD 299,758 | The ETF bought 337 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 889.49 compared to the previous average buy price of 709.163. This is 25.4% higher than average price of previous purchases of ARGX. |
| UTHR - United Therapeutics Corporation | BUY | 502 @ USD 488.51 | USD 245,232 | The ETF bought 502 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 488.51 compared to the previous average buy price of 375.98. This is 29.9% higher than average price of previous purchases of UTHR. |
| BIIB - Biogen Inc | BUY | 1,320 @ USD 172.5 | USD 227,700 | The ETF bought 1320 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 172.5 compared to the previous average buy price of 148.252. This is 16.4% higher than average price of previous purchases of BIIB. |
| ILMN - Illumina Inc | BUY | 1,567 @ USD 136.44 | USD 213,801 | The ETF bought 1567 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 136.44 compared to the previous average buy price of 104.707. This is 30.3% higher than average price of previous purchases of ILMN. |
| INCY - Incyte Corporation | BUY | 2,085 @ USD 96.1 | USD 200,369 | The ETF bought 2085 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 96.1 compared to the previous average buy price of 81.0217. This is 18.6% higher than average price of previous purchases of INCY. |
| RPRX - Royalty Pharma Plc | BUY | 4,300 @ USD 38.81 | USD 166,883 | The ETF bought 4300 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 38.81 compared to the previous average buy price of 36.6258. This is 6.0% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 288 @ USD 566.15 | USD 163,051 | The ETF bought 288 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 566.15 compared to the previous average buy price of 440.351. This is 28.6% higher than average price of previous purchases of MEDP. |
| NBIX - Neurocrine Biosciences Inc | BUY | 1,037 @ USD 154.75 | USD 160,476 | The ETF bought 1037 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 154.75 compared to the previous average buy price of 134.98. This is 14.6% higher than average price of previous purchases of NBIX. |
| RVMD - Revolution Medicines Inc | BUY | 1,900 @ USD 78.51 | USD 149,169 | The ETF bought 1900 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 78.51 compared to the previous average buy price of 49.1746. This is 59.7% higher than average price of previous purchases of RVMD. |
| BBIO - BridgeBio Pharma Inc | BUY | 2,010 @ USD 74.065 | USD 148,871 | The ETF bought 2010 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 74.065 compared to the previous average buy price of 51.3375. This is 44.3% higher than average price of previous purchases of BBIO. |
| SNY - Sanofi ADR | BUY | 2,979 @ USD 48.86 | USD 145,554 | The ETF bought 2979 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 48.86 compared to the previous average buy price of 49.9234. This is -2.1% lower than average price of previous purchases of SNY. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 881 @ USD 164.89 | USD 145,268 | The ETF bought 881 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 164.89 compared to the previous average buy price of 133.908. This is 23.1% higher than average price of previous purchases of JAZZ. |
| BNTX - BioNTech SE | BUY | 1,508 @ USD 96 | USD 144,768 | The ETF bought 1508 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 96 compared to the previous average buy price of 103.469. This is -7.2% lower than average price of previous purchases of BNTX. |
| SMMT - Summit Therapeutics PLC | BUY | 8,028 @ USD 17.99 | USD 144,424 | The ETF bought 8028 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.99 compared to the previous average buy price of 20.5806. This is -12.6% lower than average price of previous purchases of SMMT. |
| ASND - Ascendis Pharma AS | BUY | 522 @ USD 210.16 | USD 109,704 | The ETF bought 522 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 210.16 compared to the previous average buy price of 185.52. This is 13.3% higher than average price of previous purchases of ASND. |
| ROIV - Roivant Sciences Ltd | BUY | 4,910 @ USD 21.34 | USD 104,779 | The ETF bought 4910 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 21.34 compared to the previous average buy price of 15.0198. This is 42.1% higher than average price of previous purchases of ROIV. |
| VTRS - Viatris Inc | BUY | 8,870 @ USD 11.59 | USD 102,803 | The ETF bought 8870 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 11.59 compared to the previous average buy price of 9.86677. This is 17.5% higher than average price of previous purchases of VTRS. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 171 @ USD 571.33 | USD 97,697 | The ETF bought 171 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 571.33 compared to the previous average buy price of 406.518. This is 40.5% higher than average price of previous purchases of MDGL. |
| GH - Guardant Health Inc | BUY | 947 @ USD 101.38 | USD 96,007 | The ETF bought 947 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 101.38 compared to the previous average buy price of 67.6316. This is 49.9% higher than average price of previous purchases of GH. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 1,210 @ USD 79.14 | USD 95,759 | The ETF bought 1210 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 79.14 compared to the previous average buy price of 56.1717. This is 40.9% higher than average price of previous purchases of IONS. |
| EXEL - Exelixis Inc | BUY | 2,273 @ USD 41.39 | USD 94,079 | The ETF bought 2273 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 41.39 compared to the previous average buy price of 41.6896. This is -0.7% lower than average price of previous purchases of EXEL. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 1,265 @ USD 70.82 | USD 89,587 | The ETF bought 1265 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 70.82 compared to the previous average buy price of 29.0007. This is 144.2% higher than average price of previous purchases of ARWR. |
| MRNA - Moderna Inc | BUY | 2,973 @ USD 29.63 | USD 88,090 | The ETF bought 2973 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 29.63 compared to the previous average buy price of 28.1089. This is 5.4% higher than average price of previous purchases of MRNA. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 1,555 @ USD 52.99 | USD 82,399 | The ETF bought 1555 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 52.99 compared to the previous average buy price of 57.2299. This is -7.4% lower than average price of previous purchases of BMRN. |
| KRYS - Krystal Biotech Inc | BUY | 333 @ USD 246.775 | USD 82,176 | The ETF bought 333 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 246.775 compared to the previous average buy price of 174.62. This is 41.3% higher than average price of previous purchases of KRYS. |
| AXSM - Axsome Therapeutics Inc | BUY | 540 @ USD 148.75 | USD 80,325 | The ETF bought 540 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 148.75 compared to the previous average buy price of 122.585. This is 21.3% higher than average price of previous purchases of AXSM. |
| HALO - Halozyme Therapeutics Inc | BUY | 1,267 @ USD 61.9 | USD 78,427 | The ETF bought 1267 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 61.9 compared to the previous average buy price of 61.4644. This is 0.7% higher than average price of previous purchases of HALO. |
| TERN - Tern Plc | BUY | 1,663 @ USD 47.09 | USD 78,311 | The ETF bought 1663 new shares of TERN (Tern Plc). The shares were bought for an average price of 47.09 compared to the previous average buy price of 9.87908. This is 376.7% higher than average price of previous purchases of TERN. |
| NUVL - Nuvalent Inc | BUY | 733 @ USD 105.91 | USD 77,632 | The ETF bought 733 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 105.91 compared to the previous average buy price of 88.0508. This is 20.3% higher than average price of previous purchases of NUVL. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 658 @ USD 117.62 | USD 77,394 | The ETF bought 658 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 117.62 compared to the previous average buy price of 82.5893. This is 42.4% higher than average price of previous purchases of RYTM. |
| RNA - Avidity Biosciences Inc | BUY | 1,071 @ USD 71.6 | USD 76,684 | The ETF bought 1071 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.6 compared to the previous average buy price of 46.1329. This is 55.2% higher than average price of previous purchases of RNA. |
| CYTK - Cytokinetics Inc | BUY | 1,260 @ USD 60.77 | USD 76,570 | The ETF bought 1260 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 60.77 compared to the previous average buy price of 48.4763. This is 25.4% higher than average price of previous purchases of CYTK. |
| PTCT - PTC Therapeutics Inc | BUY | 982 @ USD 75.44 | USD 74,082 | The ETF bought 982 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 75.44 compared to the previous average buy price of 60.6531. This is 24.4% higher than average price of previous purchases of PTCT. |
| CRSP - Crispr Therapeutics AG | BUY | 1,265 @ USD 58.09 | USD 73,484 | The ETF bought 1265 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 58.09 compared to the previous average buy price of 53.0847. This is 9.4% higher than average price of previous purchases of CRSP. |
| PCVX - Vaxcyte Inc | BUY | 1,629 @ USD 44.59 | USD 72,637 | The ETF bought 1629 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 44.59 compared to the previous average buy price of 45.0273. This is -1.0% lower than average price of previous purchases of PCVX. |
| TVTX - Travere Therapeutics Inc | BUY | 1,905 @ USD 35.01 | USD 66,694 | The ETF bought 1905 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 35.01 compared to the previous average buy price of 23.4533. This is 49.3% higher than average price of previous purchases of TVTX. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 985 @ USD 67.44 | USD 66,428 | The ETF bought 985 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 67.44 compared to the previous average buy price of 25.6528. This is 162.9% higher than average price of previous purchases of GPCR. |
| VERA - Vera Therapeutics Inc | BUY | 1,438 @ USD 46.02 | USD 66,177 | The ETF bought 1438 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 46.02 compared to the previous average buy price of 29.1352. This is 58.0% higher than average price of previous purchases of VERA. |
| KYMR - Kymera Therapeutics Inc | BUY | 748 @ USD 87.81 | USD 65,682 | The ETF bought 748 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 87.81 compared to the previous average buy price of 51.2258. This is 71.4% higher than average price of previous purchases of KYMR. |
| HROW - Harrow Health Inc | BUY | 1,285 @ USD 51.1 | USD 65,664 | The ETF bought 1285 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 51.1 compared to the previous average buy price of 35.6704. This is 43.3% higher than average price of previous purchases of HROW. |
| FOLD - Amicus Therapeutics Inc | BUY | 6,627 @ USD 9.9 | USD 65,607 | The ETF bought 6627 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 9.9 compared to the previous average buy price of 7.95616. This is 24.4% higher than average price of previous purchases of FOLD. |
| PRAX - Praxis Precision Medicines Inc | BUY | 245 @ USD 267.28 | USD 65,484 | The ETF bought 245 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 267.28 compared to the previous average buy price of 91.5232. This is 192.0% higher than average price of previous purchases of PRAX. |
| COGT - Cogent Biosciences Inc | BUY | 1,632 @ USD 40.04 | USD 65,345 | The ETF bought 1632 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 40.04 compared to the previous average buy price of 17.5015. This is 128.8% higher than average price of previous purchases of COGT. |
| BEAM - Beam Therapeutics Inc | BUY | 2,372 @ USD 27.51 | USD 65,254 | The ETF bought 2372 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 27.51 compared to the previous average buy price of 21.6208. This is 27.2% higher than average price of previous purchases of BEAM. |
| PTGX - Protagonist Therapeutics Inc | BUY | 707 @ USD 92.25 | USD 65,221 | The ETF bought 707 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 92.25 compared to the previous average buy price of 63.7725. This is 44.7% higher than average price of previous purchases of PTGX. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 3,959 @ USD 15.88 | USD 62,869 | The ETF bought 3959 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 15.88 compared to the previous average buy price of 10.8806. This is 45.9% higher than average price of previous purchases of AUPH. |
| ALKS - Alkermes Plc | BUY | 2,147 @ USD 29.17 | USD 62,628 | The ETF bought 2147 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 29.17 compared to the previous average buy price of 30.0996. This is -3.1% lower than average price of previous purchases of ALKS. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 1,265 @ USD 49.31 | USD 62,377 | The ETF bought 1265 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 49.31 compared to the previous average buy price of 37.4319. This is 31.7% higher than average price of previous purchases of CRNX. |
| SYRE - Spyre Therapeutics Inc. | BUY | 1,794 @ USD 34.36 | USD 61,642 | The ETF bought 1794 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 34.36 compared to the previous average buy price of 20.4614. This is 67.9% higher than average price of previous purchases of SYRE. |
| VCEL - Vericel Corp Ord | BUY | 1,648 @ USD 37.39 | USD 61,619 | The ETF bought 1648 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 37.39 compared to the previous average buy price of 40.1554. This is -6.9% lower than average price of previous purchases of VCEL. |
| TWST - Twist Bioscience Corp | BUY | 1,914 @ USD 32.12 | USD 61,478 | The ETF bought 1914 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 32.12 compared to the previous average buy price of 34.9305. This is -8.0% lower than average price of previous purchases of TWST. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 1,665 @ USD 36.05 | USD 60,023 | The ETF bought 1665 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 36.05 compared to the previous average buy price of 23.8256. This is 51.3% higher than average price of previous purchases of MLYS. |
| ACLX - Arcellx Inc | BUY | 820 @ USD 72.69 | USD 59,606 | The ETF bought 820 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 72.69 compared to the previous average buy price of 72.2181. This is 0.7% higher than average price of previous purchases of ACLX. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 2,189 @ USD 27.18 | USD 59,497 | The ETF bought 2189 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 27.18 compared to the previous average buy price of 19.077. This is 42.5% higher than average price of previous purchases of CNTA. |
| OCUL - Ocular Therapeutix Inc | BUY | 4,004 @ USD 14.67 | USD 58,739 | The ETF bought 4004 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 14.67 compared to the previous average buy price of 10.4598. This is 40.3% higher than average price of previous purchases of OCUL. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 3,440 @ USD 16.9 | USD 58,136 | The ETF bought 3440 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 16.9 compared to the previous average buy price of 12.9252. This is 30.8% higher than average price of previous purchases of KALV. |
| DNLI - Denali Therapeutics Inc | BUY | 3,290 @ USD 17.37 | USD 57,147 | The ETF bought 3290 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 17.37 compared to the previous average buy price of 16.0675. This is 8.1% higher than average price of previous purchases of DNLI. |
| ARVN - Arvinas Inc | BUY | 4,387 @ USD 12.57 | USD 55,145 | The ETF bought 4387 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 12.57 compared to the previous average buy price of 9.52194. This is 32.0% higher than average price of previous purchases of ARVN. |
| HRMY - Harmony Biosciences Holdings | BUY | 1,353 @ USD 39.59 | USD 53,565 | The ETF bought 1353 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 39.59 compared to the previous average buy price of 32.9891. This is 20.0% higher than average price of previous purchases of HRMY. |
| EWTX - Edgewise Therapeutics Inc | BUY | 2,273 @ USD 23.43 | USD 53,256 | The ETF bought 2273 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 23.43 compared to the previous average buy price of 17.585. This is 33.2% higher than average price of previous purchases of EWTX. |
| SPRY - Silverback Therapeutics Inc | BUY | 4,703 @ USD 11.22 | USD 52,768 | The ETF bought 4703 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 11.22 compared to the previous average buy price of 12.5985. This is -10.9% lower than average price of previous purchases of SPRY. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 3,407 @ USD 15.42 | USD 52,536 | The ETF bought 3407 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 15.42 compared to the previous average buy price of 13.3057. This is 15.9% higher than average price of previous purchases of ADPT. |
| SRPT - Sarepta Therapeutics Inc | BUY | 2,382 @ USD 21.75 | USD 51,809 | The ETF bought 2382 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 21.75 compared to the previous average buy price of 30.736. This is -29.2% lower than average price of previous purchases of SRPT. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 628 @ USD 82.13 | USD 51,578 | The ETF bought 628 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 82.13 compared to the previous average buy price of 74.2686. This is 10.6% higher than average price of previous purchases of ANIP. |
| MNKD - MannKind Corp | BUY | 8,842 @ USD 5.81 | USD 51,372 | The ETF bought 8842 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.81 compared to the previous average buy price of 4.88669. This is 18.9% higher than average price of previous purchases of MNKD. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 2,501 @ USD 20.41 | USD 51,045 | The ETF bought 2501 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 20.41 compared to the previous average buy price of 13.4778. This is 51.4% higher than average price of previous purchases of SNDX. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 6,662 @ USD 7.58 | USD 50,498 | The ETF bought 6662 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.58 compared to the previous average buy price of 8.07406. This is -6.1% lower than average price of previous purchases of BCRX. |
| AGIO - Agios Pharm | BUY | 1,825 @ USD 27.46 | USD 50,115 | The ETF bought 1825 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 27.46 compared to the previous average buy price of 34.559. This is -20.5% lower than average price of previous purchases of AGIO. |
| INVA - Innoviva Inc | BUY | 2,423 @ USD 20.62 | USD 49,962 | The ETF bought 2423 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 20.62 compared to the previous average buy price of 19.488. This is 5.8% higher than average price of previous purchases of INVA. |
| KROS - Keros Therapeutics Inc | BUY | 2,226 @ USD 21.69 | USD 48,282 | The ETF bought 2226 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 21.69 compared to the previous average buy price of 14.883. This is 45.7% higher than average price of previous purchases of KROS. |
| ADMA - ADMA Biologics Inc | BUY | 804 @ USD 20.38 | USD 16,386 | The ETF bought 804 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 20.38 compared to the previous average buy price of 17.789. This is 14.6% higher than average price of previous purchases of ADMA. |
| SRRK - Scholar Rock Holding Corp | BUY | 324 @ USD 46.83 | USD 15,173 | The ETF bought 324 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 46.83 compared to the previous average buy price of 36.7554. This is 27.4% higher than average price of previous purchases of SRRK. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 568 @ USD 26.68 | USD 15,154 | The ETF bought 568 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 26.68 compared to the previous average buy price of 22.0051. This is 21.2% higher than average price of previous purchases of ACAD. |
| IMVT - Immunovant Inc | BUY | 590 @ USD 24.81 | USD 14,638 | The ETF bought 590 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 24.81 compared to the previous average buy price of 19.0819. This is 30.0% higher than average price of previous purchases of IMVT. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 1,062 @ USD 12.25 | USD 13,010 | The ETF bought 1062 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.25 compared to the previous average buy price of 9.59474. This is 27.7% higher than average price of previous purchases of AMRX. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 66 @ USD 183.13 | USD 12,087 | The ETF bought 66 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 183.13 compared to the previous average buy price of 148.433. This is 23.4% higher than average price of previous purchases of LGND. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 406 @ USD 29.47 | USD 11,965 | The ETF bought 406 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 29.47 compared to the previous average buy price of 19.9975. This is 47.4% higher than average price of previous purchases of ARQT. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 156 @ USD 76.53 | USD 11,939 | The ETF bought 156 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 76.53 compared to the previous average buy price of 51.5625. This is 48.4% higher than average price of previous purchases of APGE. |
| RARE - Ultragenyx | BUY | 326 @ USD 36.2 | USD 11,801 | The ETF bought 326 new shares of RARE (Ultragenyx). The shares were bought for an average price of 36.2 compared to the previous average buy price of 35.8514. This is 1.0% higher than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 326 @ USD 36.2 | USD 11,801 | The ETF bought 326 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 36.2 compared to the previous average buy price of 35.8514. This is 1.0% higher than average price of previous purchases of RARE. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 142 @ USD 81.7 | USD 11,601 | The ETF bought 142 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 81.7 compared to the previous average buy price of 56.2597. This is 45.2% higher than average price of previous purchases of TARS. |
| GRAL - GRAIL, LLC | BUY | 122 @ USD 95.06 | USD 11,597 | The ETF bought 122 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 95.06 compared to the previous average buy price of 63.4761. This is 49.8% higher than average price of previous purchases of GRAL. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 260 @ USD 43.66 | USD 11,352 | The ETF bought 260 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 43.66 compared to the previous average buy price of 37.4673. This is 16.5% higher than average price of previous purchases of XENE. |
| VCYT - Veracyte Inc | BUY | 266 @ USD 42.22 | USD 11,231 | The ETF bought 266 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 42.22 compared to the previous average buy price of 34.7996. This is 21.3% higher than average price of previous purchases of VCYT. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 170 @ USD 65.72 | USD 11,172 | The ETF bought 170 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 65.72 compared to the previous average buy price of 59.2732. This is 10.9% higher than average price of previous purchases of MIRM. |
| IRON - Ironveld Plc | BUY | 116 @ USD 93.6 | USD 10,858 | The ETF bought 116 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 93.6 compared to the previous average buy price of 65.8009. This is 42.2% higher than average price of previous purchases of IRON. |
| CGON - CG Oncology, Inc. Common stock | BUY | 258 @ USD 41.61 | USD 10,735 | The ETF bought 258 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 41.61 compared to the previous average buy price of 32.9283. This is 26.4% higher than average price of previous purchases of CGON. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 428 @ USD 24.965 | USD 10,685 | The ETF bought 428 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 24.965 compared to the previous average buy price of 21.0386. This is 18.7% higher than average price of previous purchases of APLS. |
| IDYA - Ideaya Biosciences Inc | BUY | 298 @ USD 33.56 | USD 10,001 | The ETF bought 298 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 33.56 compared to the previous average buy price of 26.1269. This is 28.4% higher than average price of previous purchases of IDYA. |
| DYN - Dyne Therapeutics Inc | BUY | 482 @ USD 19.42 | USD 9,360 | The ETF bought 482 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 19.42 compared to the previous average buy price of 14.3781. This is 35.1% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 482 @ USD 19.42 | USD 9,360 | The ETF bought 482 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 19.42 compared to the previous average buy price of 14.3781. This is 35.1% higher than average price of previous purchases of DYN. |
| WVE - Wave Life Sciences Ltd | BUY | 544 @ USD 16.75 | USD 9,112 | The ETF bought 544 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 16.75 compared to the previous average buy price of 8.18814. This is 104.6% higher than average price of previous purchases of WVE. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 190 @ USD 46.51 | USD 8,837 | The ETF bought 190 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 46.51 compared to the previous average buy price of 39.2796. This is 18.4% higher than average price of previous purchases of SUPN. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 234 @ USD 31.58 | USD 7,390 | The ETF bought 234 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 31.58 compared to the previous average buy price of 10.8238. This is 191.8% higher than average price of previous purchases of OLMA. |
| IBRX - Immunitybio Inc | BUY | 3,220 @ USD 2.19 | USD 7,052 | The ETF bought 3220 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.19 compared to the previous average buy price of 2.63704. This is -17.0% lower than average price of previous purchases of IBRX. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 326 @ USD 21.39 | USD 6,973 | The ETF bought 326 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 21.39 compared to the previous average buy price of 13.5834. This is 57.5% higher than average price of previous purchases of AVDL. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 1,462 @ USD 4.58 | USD 6,696 | The ETF bought 1462 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.58 compared to the previous average buy price of 5.53156. This is -17.2% lower than average price of previous purchases of RXRX. |
| LEGN - Legend Biotech Corp | BUY | 284 @ USD 23.01 | USD 6,535 | The ETF bought 284 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 23.01 compared to the previous average buy price of 32.9425. This is -30.2% lower than average price of previous purchases of LEGN. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 260 @ USD 24.94 | USD 6,484 | The ETF bought 260 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 24.94 compared to the previous average buy price of 17.2239. This is 44.8% higher than average price of previous purchases of ZYME. |
| TXG - 10X Genomics Inc | BUY | 388 @ USD 16.54 | USD 6,418 | The ETF bought 388 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 16.54 compared to the previous average buy price of 13.563. This is 21.9% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 388 @ USD 16.54 | USD 6,418 | The ETF bought 388 new shares of TXG (Terex Corporation). The shares were bought for an average price of 16.54 compared to the previous average buy price of 13.563. This is 21.9% higher than average price of previous purchases of TXG. |
| STOK - Stoke Therapeutics Inc | BUY | 188 @ USD 33.09 | USD 6,221 | The ETF bought 188 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 33.09 compared to the previous average buy price of 19.3914. This is 70.6% higher than average price of previous purchases of STOK. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 148 @ USD 41.01 | USD 6,069 | The ETF bought 148 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 41.01 compared to the previous average buy price of 32.6416. This is 25.6% higher than average price of previous purchases of KNSA. |
| TSHA - Taysha Gene Therapies Inc | BUY | 924 @ USD 5.76 | USD 5,322 | The ETF bought 924 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 5.76 compared to the previous average buy price of 3.22851. This is 78.4% higher than average price of previous purchases of TSHA. |
| NRIX - Nurix Therapeutics Inc | BUY | 272 @ USD 19.07 | USD 5,187 | The ETF bought 272 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 19.07 compared to the previous average buy price of 13.1287. This is 45.3% higher than average price of previous purchases of NRIX. |
| NVCR - Novocure Ltd | BUY | 378 @ USD 13.66 | USD 5,163 | The ETF bought 378 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 13.66 compared to the previous average buy price of 15.4302. This is -11.5% lower than average price of previous purchases of NVCR. |
| COLL - Collegium Pharmaceutical Inc | BUY | 106 @ USD 48.36 | USD 5,126 | The ETF bought 106 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 48.36 compared to the previous average buy price of 35.414. This is 36.6% higher than average price of previous purchases of COLL. |
| IMCR - Immunocore Holdings Ltd | BUY | 138 @ USD 35.8 | USD 4,940 | The ETF bought 138 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 35.8 compared to the previous average buy price of 34.2776. This is 4.4% higher than average price of previous purchases of IMCR. |
| ARDX - Ardelyx Inc | BUY | 818 @ USD 5.9 | USD 4,826 | The ETF bought 818 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.9 compared to the previous average buy price of 4.90685. This is 20.2% higher than average price of previous purchases of ARDX. |
| FTRE - Fortrea Holdings Inc. | BUY | 308 @ USD 15.55 | USD 4,789 | The ETF bought 308 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 15.55 compared to the previous average buy price of 8.27423. This is 87.9% higher than average price of previous purchases of FTRE. |
| GMAB - Genmab AS | BUY | 142 @ USD 32.3 | USD 4,587 | The ETF bought 142 new shares of GMAB (Genmab AS). The shares were bought for an average price of 32.3 compared to the previous average buy price of 25.4032. This is 27.1% higher than average price of previous purchases of GMAB. |
| RLAY - Relay Therapeutics Inc | BUY | 586 @ USD 7.79 | USD 4,565 | The ETF bought 586 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.79 compared to the previous average buy price of 4.86009. This is 60.3% higher than average price of previous purchases of RLAY. |
| SANA - Sana Biotechnology Inc | BUY | 894 @ USD 5 | USD 4,470 | The ETF bought 894 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 5 compared to the previous average buy price of 3.46637. This is 44.2% higher than average price of previous purchases of SANA. |
| DVAX - Dynavax Technologies Corporation | BUY | 398 @ USD 10.86 | USD 4,322 | The ETF bought 398 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 10.86 compared to the previous average buy price of 10.6503. This is 2.0% higher than average price of previous purchases of DVAX. |
| ANAB - AnaptysBio Inc | BUY | 94 @ USD 45.78 | USD 4,303 | The ETF bought 94 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 45.78 compared to the previous average buy price of 28.2393. This is 62.1% higher than average price of previous purchases of ANAB. |
| XNCR - Xencor Inc | BUY | 242 @ USD 17.06 | USD 4,129 | The ETF bought 242 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 17.06 compared to the previous average buy price of 12.4528. This is 37.0% higher than average price of previous purchases of XNCR. |
| AMPH - Amphastar P | BUY | 158 @ USD 25.9 | USD 4,092 | The ETF bought 158 new shares of AMPH (Amphastar P). The shares were bought for an average price of 25.9 compared to the previous average buy price of 25.8239. This is 0.3% higher than average price of previous purchases of AMPH. |
| SVRA - Savara Inc | BUY | 588 @ USD 6.94 | USD 4,081 | The ETF bought 588 new shares of SVRA (Savara Inc). The shares were bought for an average price of 6.94 compared to the previous average buy price of 3.65134. This is 90.1% higher than average price of previous purchases of SVRA. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 568 @ USD 7.01 | USD 3,982 | The ETF bought 568 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.01 compared to the previous average buy price of 6.21357. This is 12.8% higher than average price of previous purchases of XERS. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 304 @ USD 13.07 | USD 3,973 | The ETF bought 304 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 13.07 compared to the previous average buy price of 8.34988. This is 56.5% higher than average price of previous purchases of AMLX. |
| PCRX - Pacira BioSciences, Inc. | BUY | 152 @ USD 25.73 | USD 3,911 | The ETF bought 152 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 25.73 compared to the previous average buy price of 23.8182. This is 8.0% higher than average price of previous purchases of PCRX. |
| GRFS - Grifols SA ADR | BUY | 418 @ USD 9.16 | USD 3,829 | The ETF bought 418 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.16 compared to the previous average buy price of 9.21653. This is -0.6% lower than average price of previous purchases of GRFS. |
| ABCL - Abcellera Biologics Inc | BUY | 1,022 @ USD 3.74 | USD 3,822 | The ETF bought 1022 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.74 compared to the previous average buy price of 3.84329. This is -2.7% lower than average price of previous purchases of ABCL. |
| ELVN - Enliven Therapeutics Inc. | BUY | 202 @ USD 18.77 | USD 3,792 | The ETF bought 202 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 18.77 compared to the previous average buy price of 20.6004. This is -8.9% lower than average price of previous purchases of ELVN. |
| PGEN - Precigen Inc | BUY | 1,044 @ USD 3.62 | USD 3,779 | The ETF bought 1044 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.62 compared to the previous average buy price of 2.68177. This is 35.0% higher than average price of previous purchases of PGEN. |
| CSTL - Castle Biosciences Inc | BUY | 98 @ USD 37.97 | USD 3,721 | The ETF bought 98 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 37.97 compared to the previous average buy price of 26.0322. This is 45.9% higher than average price of previous purchases of CSTL. |
| NVAX - Novavax Inc | BUY | 556 @ USD 6.69 | USD 3,720 | The ETF bought 556 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 6.69 compared to the previous average buy price of 7.21324. This is -7.3% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 556 @ USD 6.69 | USD 3,720 | The ETF bought 556 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 6.69 compared to the previous average buy price of 7.21324. This is -7.3% lower than average price of previous purchases of NVAX. |
| QURE - Uniqure NV | BUY | 188 @ USD 19.75 | USD 3,713 | The ETF bought 188 new shares of QURE (Uniqure NV). The shares were bought for an average price of 19.75 compared to the previous average buy price of 23.4994. This is -16.0% lower than average price of previous purchases of QURE. |
| URGN - UroGen Pharma Ltd | BUY | 164 @ USD 22.36 | USD 3,667 | The ETF bought 164 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 22.36 compared to the previous average buy price of 16.9321. This is 32.1% higher than average price of previous purchases of URGN. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 248 @ USD 14.57 | USD 3,613 | The ETF bought 248 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.57 compared to the previous average buy price of 10.4663. This is 39.2% higher than average price of previous purchases of PHAT. |
| NTLA - Intellia Therapeutics Inc | BUY | 372 @ USD 9.55 | USD 3,553 | The ETF bought 372 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 9.55 compared to the previous average buy price of 11.5384. This is -17.2% lower than average price of previous purchases of NTLA. |
| ERAS - Erasca Inc | BUY | 1,044 @ USD 3.38 | USD 3,529 | The ETF bought 1044 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 3.38 compared to the previous average buy price of 2.00052. This is 69.0% higher than average price of previous purchases of ERAS. |
| TNGX - Tango Therapeutics Inc | BUY | 382 @ USD 9.1 | USD 3,476 | The ETF bought 382 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 9.1 compared to the previous average buy price of 7.24071. This is 25.7% higher than average price of previous purchases of TNGX. |
| MNMD - Mind Medicine Inc | BUY | 266 @ USD 12.59 | USD 3,349 | The ETF bought 266 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 12.59 compared to the previous average buy price of 9.47874. This is 32.8% higher than average price of previous purchases of MNMD. |
| KURA - Kura Oncology Inc | BUY | 310 @ USD 10.46 | USD 3,243 | The ETF bought 310 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 10.46 compared to the previous average buy price of 8.24451. This is 26.9% higher than average price of previous purchases of KURA. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 334 @ USD 9.69 | USD 3,236 | The ETF bought 334 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 9.69 compared to the previous average buy price of 10.6659. This is -9.1% lower than average price of previous purchases of ORIC. |
| JANX - Janux Therapeutics Inc | BUY | 206 @ USD 15.36 | USD 3,164 | The ETF bought 206 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 15.36 compared to the previous average buy price of 26.4355. This is -41.9% lower than average price of previous purchases of JANX. |
| VIR - Vir Biotechnology Inc | BUY | 476 @ USD 6.63 | USD 3,156 | The ETF bought 476 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 6.63 compared to the previous average buy price of 5.91512. This is 12.1% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 476 @ USD 6.63 | USD 3,156 | The ETF bought 476 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 6.63 compared to the previous average buy price of 5.91512. This is 12.1% higher than average price of previous purchases of VIR. |
| ABUS - Arbutus Biopharma Corp | BUY | 674 @ USD 4.67 | USD 3,148 | The ETF bought 674 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.67 compared to the previous average buy price of 3.82006. This is 22.2% higher than average price of previous purchases of ABUS. |
| TBPH - Theravance Biopharma Inc | BUY | 174 @ USD 17.68 | USD 3,076 | The ETF bought 174 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 17.68 compared to the previous average buy price of 13.4727. This is 31.2% higher than average price of previous purchases of TBPH. |
| GERN - Geron Corporation | BUY | 2,190 @ USD 1.39 | USD 3,044 | The ETF bought 2190 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.39 compared to the previous average buy price of 1.43887. This is -3.4% lower than average price of previous purchases of GERN. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 352 @ USD 8.42 | USD 2,964 | The ETF bought 352 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.42 compared to the previous average buy price of 7.7112. This is 9.2% higher than average price of previous purchases of DAWN. |
| ZLAB - Zai Lab Ltd | BUY | 164 @ USD 17.82 | USD 2,922 | The ETF bought 164 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 17.82 compared to the previous average buy price of 31.2909. This is -43.1% lower than average price of previous purchases of ZLAB. |
| PAHC - Phibro Animal Health Corporation | BUY | 68 @ USD 40.76 | USD 2,772 | The ETF bought 68 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 40.76 compared to the previous average buy price of 31.3653. This is 30.0% higher than average price of previous purchases of PAHC. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 1,230 @ USD 2.25 | USD 2,768 | The ETF bought 1230 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.25 compared to the previous average buy price of 2.39746. This is -6.2% lower than average price of previous purchases of IOVA. |
| REPL - Replimune Group Inc | BUY | 276 @ USD 9.86999 | USD 2,724 | The ETF bought 276 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 9.86999 compared to the previous average buy price of 9.13873. This is 8.0% higher than average price of previous purchases of REPL. |
| CGEM - Cullinan Oncology LLC | BUY | 212 @ USD 12.38 | USD 2,625 | The ETF bought 212 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 12.38 compared to the previous average buy price of 8.517. This is 45.4% higher than average price of previous purchases of CGEM. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 606 @ USD 4.27 | USD 2,588 | The ETF bought 606 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 4.27 compared to the previous average buy price of 4.35037. This is -1.8% lower than average price of previous purchases of PRME. |
| MGTX - MeiraGTx Holdings PLC | BUY | 278 @ USD 8.71999 | USD 2,424 | The ETF bought 278 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 8.71999 compared to the previous average buy price of 7.41684. This is 17.6% higher than average price of previous purchases of MGTX. |
| PACB - Pacific Biosciences of California | BUY | 1,098 @ USD 2.17 | USD 2,383 | The ETF bought 1098 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.17 compared to the previous average buy price of 1.69177. This is 28.3% higher than average price of previous purchases of PACB. |
| RGNX - Regenxbio Inc | BUY | 182 @ USD 12.85 | USD 2,339 | The ETF bought 182 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 12.85 compared to the previous average buy price of 9.97923. This is 28.8% higher than average price of previous purchases of RGNX. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 604 @ USD 3.68 | USD 2,223 | The ETF bought 604 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.68 compared to the previous average buy price of 2.32458. This is 58.3% higher than average price of previous purchases of IRWD. |
| LYEL - Lyell Immunopharma Inc | BUY | 66 @ USD 33.41 | USD 2,205 | The ETF bought 66 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 33.41 compared to the previous average buy price of 8.27078. This is 304.0% higher than average price of previous purchases of LYEL. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 540 @ USD 3.71 | USD 2,003 | The ETF bought 540 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.71 compared to the previous average buy price of 2.92619. This is 26.8% higher than average price of previous purchases of MRVI. |
| PRTA - Prothena Corporation plc | BUY | 190 @ USD 10.33 | USD 1,963 | The ETF bought 190 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.33 compared to the previous average buy price of 9.44113. This is 9.4% higher than average price of previous purchases of PRTA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 174 @ USD 10.92 | USD 1,900 | The ETF bought 174 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.92 compared to the previous average buy price of 7.68532. This is 42.1% higher than average price of previous purchases of FDMT. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 1,312 @ USD 1.32 | USD 1,732 | The ETF bought 1312 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.32 compared to the previous average buy price of 1.15474. This is 14.3% higher than average price of previous purchases of LXRX. |
| GLPG - Galapagos NV ADR | BUY | 52 @ USD 32.57 | USD 1,694 | The ETF bought 52 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 32.57 compared to the previous average buy price of 29.7023. This is 9.7% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 52 @ USD 32.57 | USD 1,694 | The ETF bought 52 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 32.57 compared to the previous average buy price of 29.7023. This is 9.7% higher than average price of previous purchases of GLPG. |
| EOLS - Evolus Inc | BUY | 242 @ USD 6.91 | USD 1,672 | The ETF bought 242 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.91 compared to the previous average buy price of 8.59891. This is -19.6% lower than average price of previous purchases of EOLS. |
| ALT - Altitude Group Plc | BUY | 296 @ USD 5.34 | USD 1,581 | The ETF bought 296 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 5.34 compared to the previous average buy price of 5.14128. This is 3.9% higher than average price of previous purchases of ALT. |
| SIGA - SIGA Technologies Inc | BUY | 242 @ USD 6.52 | USD 1,578 | The ETF bought 242 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.52 compared to the previous average buy price of 6.63704. This is -1.8% lower than average price of previous purchases of SIGA. |
| TRDA - Entrada Therapeutics Inc | BUY | 142 @ USD 10.81 | USD 1,535 | The ETF bought 142 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.81 compared to the previous average buy price of 8.1827. This is 32.1% higher than average price of previous purchases of TRDA. |
| HCM - HUTCHMED China Ltd | BUY | 110 @ USD 13.6 | USD 1,496 | The ETF bought 110 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 13.6 compared to the previous average buy price of 15.1879. This is -10.5% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 110 @ USD 13.6 | USD 1,496 | The ETF bought 110 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 13.6 compared to the previous average buy price of 15.1879. This is -10.5% lower than average price of previous purchases of HCM. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 222 @ USD 6.59999 | USD 1,465 | The ETF bought 222 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 6.59999 compared to the previous average buy price of 4.90541. This is 34.5% higher than average price of previous purchases of VNDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 370 @ USD 3.45001 | USD 1,277 | The ETF bought 370 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.45001 compared to the previous average buy price of 4.66928. This is -26.1% lower than average price of previous purchases of RCKT. |
| AVXL - Anavex Life Sciences Corp | BUY | 298 @ USD 4.11 | USD 1,225 | The ETF bought 298 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 4.11 compared to the previous average buy price of 8.14738. This is -49.6% lower than average price of previous purchases of AVXL. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 162 @ USD 7.42999 | USD 1,204 | The ETF bought 162 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 7.42999 compared to the previous average buy price of 8.16928. This is -9.0% lower than average price of previous purchases of BCYC. |
| AUTL - Autolus Therapeutics Ltd | BUY | 756 @ USD 1.59 | USD 1,202 | The ETF bought 756 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.59 compared to the previous average buy price of 1.74456. This is -8.9% lower than average price of previous purchases of AUTL. |
| ALLO - Allogene Therapeutics Inc | BUY | 762 @ USD 1.55 | USD 1,181 | The ETF bought 762 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.55 compared to the previous average buy price of 1.34377. This is 15.3% higher than average price of previous purchases of ALLO. |
| ACIU - AC Immune Ltd | BUY | 348 @ USD 3.22 | USD 1,121 | The ETF bought 348 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.22 compared to the previous average buy price of 2.552. This is 26.2% higher than average price of previous purchases of ACIU. |
| OABI - OmniAb Inc. | BUY | 430 @ USD 2.16 | USD 929 | The ETF bought 430 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 2.16 compared to the previous average buy price of 1.88357. This is 14.7% higher than average price of previous purchases of OABI. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 290 @ USD 3.19 | USD 925 | The ETF bought 290 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3.19 compared to the previous average buy price of 3.25351. This is -2.0% lower than average price of previous purchases of AVIR. |
| EDIT - Editas Medicine Inc | BUY | 332 @ USD 2.56 | USD 850 | The ETF bought 332 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.56 compared to the previous average buy price of 2.61833. This is -2.2% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 178 @ USD 4.40999 | USD 785 | The ETF bought 178 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.40999 compared to the previous average buy price of 3.92343. This is 12.4% higher than average price of previous purchases of VYGR. |
| HUMA - Humacyte Inc | BUY | 566 @ USD 1.31 | USD 741 | The ETF bought 566 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.31 compared to the previous average buy price of 2.00118. This is -34.5% lower than average price of previous purchases of HUMA. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 98 @ USD 7.52 | USD 737 | The ETF bought 98 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.52 compared to the previous average buy price of 12.5522. This is -40.1% lower than average price of previous purchases of ARCT. |
| MXCT - MaxCyte Inc | BUY | 370 @ USD 1.60001 | USD 592 | The ETF bought 370 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.60001 compared to the previous average buy price of 2.00977. This is -20.4% lower than average price of previous purchases of MXCT. |
| ALEC - Alector Inc | BUY | 368 @ USD 1.46 | USD 537 | The ETF bought 368 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.46 compared to the previous average buy price of 1.71106. This is -14.7% lower than average price of previous purchases of ALEC. |
| MRSN - Mersana Therapeutics Inc | BUY | 16 @ USD 28.2301 | USD 452 | The ETF bought 16 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 28.2301 compared to the previous average buy price of 1.26586. This is 2,130.1% higher than average price of previous purchases of MRSN. |
| FATE - Fate Therapeutics Inc | BUY | 380 @ USD 1.11001 | USD 422 | The ETF bought 380 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.11001 compared to the previous average buy price of 1.14721. This is -3.2% lower than average price of previous purchases of FATE. |
| BMEA - Biomea Fusion Inc | BUY | 240 @ USD 1.52 | USD 365 | The ETF bought 240 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.52 compared to the previous average buy price of 1.51568. This is 0.3% higher than average price of previous purchases of BMEA. |
| MGNX - MacroGenics Inc | BUY | 214 @ USD 1.40999 | USD 302 | The ETF bought 214 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.40999 compared to the previous average buy price of 1.5322. This is -8.0% lower than average price of previous purchases of MGNX. |
| PLRX - Pliant Therapeutics Inc | BUY | 200 @ USD 1.32001 | USD 264 | The ETF bought 200 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.32001 compared to the previous average buy price of 1.48357. This is -11.0% lower than average price of previous purchases of PLRX. |
| STRO - Sutro Biopharma | BUY | 26 @ USD 9.81006 | USD 255 | The ETF bought 26 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 9.81006 compared to the previous average buy price of 1.00856. This is 872.7% higher than average price of previous purchases of STRO. |
| OKUR - OKUR | BUY | 42 @ USD 3.22995 | USD 136 | The ETF bought 42 new shares of OKUR (OKUR). The shares were bought for an average price of 3.22995 compared to the previous average buy price of 5.59308. This is -42.3% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-11 this would crystalise an overall loss. |